The future of intravenous iron in nephrology

Daniel W. Coyne

doi:10.1093/ndtplus/sfr040

The future of intravenous iron in nephrology

Daniel W. Coyne

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Management of anaemia in chronic kidney disease (CKD) patients can be difficult and expensive. The recently completed Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), the largest double-blinded trial of erythropoiesis-stimulating agents (ESA) treatment in CKD to date, provides us with a wealth of new information on the natural history of anaemia in Stage 3 and 4 CKD and the risks and benefits of use of ESAs. This section will discuss some of the TREAT trial results in the context of other recent studies of ESAs and intravenous iron in CKD patients. It will also review applying those results when choosing anaemia goals for an individual, and determining if iron therapy might improve anaemia.

Original language	English
Pages (from-to)	i6-i9
Journal	NDT Plus
Volume	4
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1093/ndtplus/sfr040
State	Published - May 2011

Keywords

Iron
anemia
chronic kidney disease
epoetin
stroke
transfusion

Access to Document

10.1093/ndtplus/sfr040

Cite this

@article{fcc2ce3a1cb649b89f56f53c765d6317,

title = "The future of intravenous iron in nephrology",

abstract = "Management of anaemia in chronic kidney disease (CKD) patients can be difficult and expensive. The recently completed Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), the largest double-blinded trial of erythropoiesis-stimulating agents (ESA) treatment in CKD to date, provides us with a wealth of new information on the natural history of anaemia in Stage 3 and 4 CKD and the risks and benefits of use of ESAs. This section will discuss some of the TREAT trial results in the context of other recent studies of ESAs and intravenous iron in CKD patients. It will also review applying those results when choosing anaemia goals for an individual, and determining if iron therapy might improve anaemia.",

keywords = "Iron, anemia, chronic kidney disease, epoetin, stroke, transfusion",

author = "Coyne, {Daniel W.}",

year = "2011",

month = may,

doi = "10.1093/ndtplus/sfr040",

language = "English",

volume = "4",

pages = "i6--i9",

journal = "NDT Plus",

issn = "1753-0784",

number = "SUPPL. 1",

}

TY - JOUR

T1 - The future of intravenous iron in nephrology

AU - Coyne, Daniel W.

PY - 2011/5

Y1 - 2011/5

N2 - Management of anaemia in chronic kidney disease (CKD) patients can be difficult and expensive. The recently completed Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), the largest double-blinded trial of erythropoiesis-stimulating agents (ESA) treatment in CKD to date, provides us with a wealth of new information on the natural history of anaemia in Stage 3 and 4 CKD and the risks and benefits of use of ESAs. This section will discuss some of the TREAT trial results in the context of other recent studies of ESAs and intravenous iron in CKD patients. It will also review applying those results when choosing anaemia goals for an individual, and determining if iron therapy might improve anaemia.

AB - Management of anaemia in chronic kidney disease (CKD) patients can be difficult and expensive. The recently completed Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), the largest double-blinded trial of erythropoiesis-stimulating agents (ESA) treatment in CKD to date, provides us with a wealth of new information on the natural history of anaemia in Stage 3 and 4 CKD and the risks and benefits of use of ESAs. This section will discuss some of the TREAT trial results in the context of other recent studies of ESAs and intravenous iron in CKD patients. It will also review applying those results when choosing anaemia goals for an individual, and determining if iron therapy might improve anaemia.

KW - Iron

KW - anemia

KW - chronic kidney disease

KW - epoetin

KW - stroke

KW - transfusion

UR - http://www.scopus.com/inward/record.url?scp=79958013709&partnerID=8YFLogxK

U2 - 10.1093/ndtplus/sfr040

DO - 10.1093/ndtplus/sfr040

M3 - Article

C2 - 27045558

AN - SCOPUS:79958013709

SN - 1753-0784

VL - 4

SP - i6-i9

JO - NDT Plus

JF - NDT Plus

IS - SUPPL. 1

ER -

The future of intravenous iron in nephrology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this